Procyrion, Inc. Secures $50 Million in Series A Funding to Advance Revolutionary Aortix™ Catheter-Deployed Pump Technology

Procyrion, Inc., a pioneering medical device firm specializing in innovative solutions for patients suffering from cardiac and renal impairment, has successfully raised $50 million in its latest funding round. This substantial investment underscores the growing recognition of the company's commitment to address critical healthcare challenges and improve patient outcomes through its advanced catheter-deployed pump technology. At the forefront of this initiative is Aortix™, an investigational percutaneous mechanical circulatory support device designed to treat cardiorenal syndrome via a rapidly-deployed intra-aortic catheter system. Aortix™ holds the potential to revolutionize the management of this condition, which affects numerous patients globally and has long been underserved in terms of effective treatment options. The newly acquired funds will be instrumental in propelling Procyrion’s research and development efforts, enabling the company to advance Aortix™ through the necessary clinical trials and regulatory processes. As Procyrion continues to navigate its journey toward bringing Aortix™ to market, this latest infusion of capital reflects confidence from investors and the medical community alike in the company's vision and expertise. While Aortix™ is currently not available for sale anywhere due to its investigational status, the funding is a vital step forward in addressing the significant unmet needs of those impacted by cardiorenal syndrome. Procyrion remains dedicated to the mission of transforming the landscape of cardiac and renal care and looks forward to sharing pivotal developments on this exciting path ahead.